ATV

DRUG15 trials

Conditions

Acquired Immune Deficiency Syndrome (AIDS)Acquired Immunodeficiency SyndromeHIVHIV InfectionsHIV-1 InfectionHIV-1-infectionHepatitis C

Phase 1

Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents

CompletedNCT00006604

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2000-11-30End: 2014-09-30Updated: 2021-11-05

Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.

CompletedNCT01565889

Gilead SciencesHepatitis C, HIV

Start: 2012-03-31End: 2013-11-30Updated: 2014-10-01

Phase 2

Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

CompletedNCT00892437

Gilead SciencesHIV-1 Infection

Start: 2009-05-31End: 2015-01-31Updated: 2016-02-15

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

Active, not recruitingNCT02016924

Gilead SciencesAcquired Immune Deficiency Syndrome (AIDS), HIV Infections

Start: 2014-01-16End: 2027-03-01Updated: 2026-03-20

Phase 3

BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada

CompletedNCT00272779

Bristol-Myers SquibbHIV Infections

Start: 2005-11-30End: 2008-10-31Updated: 2011-05-09

Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

CompletedNCT01106586

Gilead SciencesHIV, HIV Infections

Start: 2010-04-30End: 2014-09-30Updated: 2015-11-11

Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

CompletedNCT01108510

Gilead SciencesHIV, HIV Infections

Start: 2010-04-30End: 2015-04-30Updated: 2016-05-23

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

CompletedNCT01363011

Gilead SciencesAcquired Immunodeficiency Syndrome, HIV Infections

Start: 2011-05-31End: 2015-02-28Updated: 2016-05-02

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

CompletedNCT01705574

Gilead SciencesAcquired Immunodeficiency Syndrome, HIV Infections

Start: 2012-10-24End: 2018-09-06Updated: 2019-09-20

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

CompletedNCT01815736

Gilead SciencesHIV, HIV Infections

Start: 2013-03-27End: 2020-04-01Updated: 2021-04-13

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

CompletedNCT01967940

Gilead SciencesAcquired Immunodeficiency Syndrome, HIV, HIV Infections

Start: 2013-10-25End: 2017-07-31Updated: 2018-11-16

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

CompletedNCT02603107

Gilead SciencesHIV-1 Infection

Start: 2015-11-20End: 2019-12-23Updated: 2020-12-29

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

CompletedNCT02652624

Gilead SciencesHIV-1 Infection

Start: 2016-02-19End: 2018-11-26Updated: 2020-03-04

Phase 4

Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults

CompletedNCT02246998

Gilead SciencesHIV-1 Infection

Start: 2014-12-15End: 2016-02-17Updated: 2018-01-03

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

RecruitingNCT06337032

Gilead SciencesHIV-1-infection

Start: 2024-08-27End: 2034-03-01Target: 350Updated: 2026-03-16

HIV Medicine2022-08-178 citations

Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development.

2022-05-1914 citations

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

Carolina Digital Repository (University of North Carolina at Chapel Hill)2020-04-22

Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial

JAIDS Journal of Acquired Immune Deficiency Syndromes2019-10-1454 citations

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.

2018-06-18125 citations

Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment

AIDS Research and Human Retroviruses2018-01-2588 citations

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.

2017-03-0257 citations

Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial.

2017-01-015 citations

Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.

2016-05-2768 citations

2015-11-02223 citations

Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV-1-Infected Patients Aged<b>≥</b>3 to <12 Years

CPT Pharmacometrics & Systems Pharmacology2015-06-1912 citations

Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV.

2015-04-0119 citations

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.

2012-06-01260 citations

Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.

2011-11-2517 citations

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.

2010-12-0935 citations

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

2008-08-01267 citations

ATV

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Phase 4

Related Papers